Rhenman & Partners Asset Management AB
Latest statistics and disclosures from Rhenman & Partners Asset Management AB's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LLY, HZNP, ABBV, UNH, MCK, and represent 15.88% of Rhenman & Partners Asset Management AB's stock portfolio.
- Added to shares of these 10 stocks: REGN (+$20M), BNTX (+$15M), ALGN (+$6.5M), CYTK (+$5.3M), ABMD (+$5.3M), GDRX, SWAV, RVNC, ISRG, NTLA.
- Started 5 new stock positions in NTLA, RVNC, GDRX, REGN, BNTX.
- Reduced shares in these 10 stocks: UNH (-$32M), ANTM (-$25M), MCK (-$25M), JNJ (-$25M), PFE (-$25M), ABBV (-$23M), BIIB (-$21M), VRTX (-$20M), BSX (-$18M), CVS (-$18M).
- Sold out of its positions in DCPH, EPZM, FGEN, HCA, INNV, SAGE, Vocera Communications, ZBH.
- Rhenman & Partners Asset Management AB was a net seller of stock by $-433M.
- Rhenman & Partners Asset Management AB has $1.0B in assets under management (AUM), dropping by -32.60%.
- Central Index Key (CIK): 0001599882
Tip: Access up to 7 years of quarterly data
Positions held by Rhenman & Partners Asset Management AB consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rhenman & Partners Asset Management AB
Companies in the Rhenman & Partners Asset Management AB portfolio as of the March 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Eli Lilly & Co. (LLY) | 3.5 | $35M | -27% | 124k | 286.37 | |
| Horizon Therapeutics Pub L SHS (HZNP) | 3.5 | $35M | -20% | 336k | 105.21 | |
| Abbvie (ABBV) | 3.1 | $32M | -41% | 195k | 162.11 | |
| UnitedHealth (UNH) | 2.9 | $30M | -51% | 58k | 509.97 | |
| McKesson Corporation (MCK) | 2.9 | $29M | -46% | 95k | 306.13 | |
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 2.8 | $28M | -37% | 182k | 155.67 | |
| Pfizer (PFE) | 2.7 | $27M | -47% | 523k | 51.77 | |
| Cigna Corp (CI) | 2.6 | $27M | -20% | 112k | 239.61 | |
| CVS Caremark Corporation (CVS) | 2.3 | $24M | -42% | 235k | 101.21 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.3 | $23M | -45% | 90k | 260.97 | |
| Anthem (ANTM) | 2.2 | $23M | -52% | 46k | 491.22 | |
| Boston Scientific Corporation (BSX) | 2.2 | $23M | -43% | 510k | 44.29 | |
| Abiomed (ABMD) | 2.2 | $23M | +30% | 68k | 331.24 | |
| Alnylam Pharmaceuticals (ALNY) | 2.1 | $21M | -25% | 130k | 163.29 | |
Setup an alertRhenman & Partners Asset Management AB will file the next quarterly 13-HR in about 3 months. Would you like to be notified? |
||||||
| Johnson & Johnson (JNJ) | 2.0 | $20M | -55% | 113k | 177.23 | |
| Regeneron Pharmaceuticals (REGN) | 2.0 | $20M | NEW | 29k | 698.42 | |
| Cooper Cos Com New (COO) | 1.9 | $19M | -15% | 46k | 417.59 | |
| Apellis Pharmaceuticals (APLS) | 1.9 | $19M | -12% | 377k | 50.81 | |
| Merck & Co (MRK) | 1.8 | $19M | -25% | 225k | 82.05 | |
| Medtronic SHS (MDT) | 1.8 | $18M | -45% | 160k | 110.95 | |
| Tenet Healthcare Corp Com New (THC) | 1.7 | $18M | -3% | 203k | 85.96 | |
| Intra Cellular Therapies (ITCI) | 1.7 | $17M | -28% | 280k | 61.19 | |
| BioMarin Pharmaceutical (BMRN) | 1.7 | $17M | -16% | 220k | 77.10 | |
| AmerisourceBergen (ABC) | 1.6 | $17M | -50% | 108k | 154.71 | |
| Biohaven Pharmaceutical Holding (BHVN) | 1.6 | $16M | -9% | 136k | 118.57 | |
| Intuitive Surgical Com New (ISRG) | 1.6 | $16M | +31% | 53k | 301.68 | |
| Centene Corporation (CNC) | 1.6 | $16M | -26% | 187k | 84.19 | |
| Axonics Modulation Technolog (AXNX) | 1.5 | $15M | -23% | 240k | 62.60 | |
| Biontech Se Sponsored Ads (BNTX) | 1.4 | $15M | NEW | 85k | 170.56 | |
| Thermo Fisher Scientific (TMO) | 1.4 | $14M | -46% | 24k | 590.65 | |
| Align Technology (ALGN) | 1.3 | $13M | +100% | 30k | 436.00 | |
| Harmony Biosciences Hldgs In (HRMY) | 1.3 | $13M | +21% | 268k | 48.65 | |
| Mirati Therapeutics (MRTX) | 1.2 | $12M | 150k | 82.22 | ||
| Inspire Med Sys (INSP) | 1.2 | $12M | +2% | 48k | 256.69 | |
| Becton, Dickinson and (BDX) | 1.2 | $12M | -51% | 45k | 266.00 | |
| Humana (HUM) | 1.1 | $12M | -51% | 27k | 435.17 | |
| Shockwave Med (SWAV) | 1.1 | $11M | +61% | 55k | 207.35 | |
| Cytokinetics Com New (CYTK) | 1.1 | $11M | +96% | 295k | 36.81 | |
| Abbott Laboratories (ABT) | 1.1 | $11M | -10% | 90k | 118.36 | |
| Privia Health Group (PRVA) | 1.0 | $11M | -31% | 398k | 26.73 | |
| Gilead Sciences (GILD) | 1.0 | $10M | -38% | 170k | 59.45 | |
| Danaher Corporation (DHR) | 1.0 | $10M | -5% | 34k | 293.32 | |
| Neurocrine Biosciences (NBIX) | 1.0 | $9.8M | -30% | 105k | 93.75 | |
| Xencor (XNCR) | 0.9 | $9.2M | -23% | 344k | 26.68 | |
| Seagen (SGEN) | 0.9 | $8.8M | -51% | 61k | 144.05 | |
| Veeva Sys Cl A Com (VEEV) | 0.8 | $8.1M | -36% | 38k | 212.45 | |
| Iovance Biotherapeutics (IOVA) | 0.8 | $7.9M | -20% | 475k | 16.65 | |
| Edwards Lifesciences (EW) | 0.8 | $7.7M | -35% | 65k | 117.72 | |
| R1 Rcm (RCM) | 0.7 | $7.6M | -48% | 282k | 26.76 | |
| Dynavax Technologies Corp Com New (DVAX) | 0.7 | $7.4M | -9% | 681k | 10.84 | |
| Meiragtx Holdings (MGTX) | 0.7 | $6.9M | +11% | 500k | 13.85 | |
| ImmunoGen (IMGN) | 0.7 | $6.8M | -5% | 1.4M | 4.76 | |
| Teladoc (TDOC) | 0.7 | $6.6M | -26% | 92k | 72.13 | |
| Guardant Health (GH) | 0.6 | $6.3M | -52% | 95k | 66.24 | |
| Silk Road Medical Inc Common (SILK) | 0.6 | $6.2M | -25% | 150k | 41.29 | |
| Glaukos (GKOS) | 0.6 | $6.1M | -39% | 105k | 57.82 | |
| Novocure Ord Shs (NVCR) | 0.6 | $5.8M | -42% | 70k | 82.86 | |
| Aerie Pharmaceuticals (AERI) | 0.5 | $5.4M | -21% | 589k | 9.10 | |
| EXACT Sciences Corporation (EXAS) | 0.5 | $5.3M | -30% | 76k | 69.92 | |
| Progyny (PGNY) | 0.5 | $5.1M | 100k | 51.40 | ||
| Immunocore Hldgs Ads (IMCR) | 0.5 | $5.1M | +89% | 171k | 29.90 | |
| Alkermes SHS (ALKS) | 0.5 | $4.7M | -14% | 180k | 26.31 | |
| Health Catalyst (HCAT) | 0.5 | $4.7M | -25% | 180k | 26.13 | |
| Esperion Therapeutics (ESPR) | 0.4 | $4.6M | 982k | 4.64 | ||
| Goodrx Hldgs Com Cl A (GDRX) | 0.4 | $4.5M | NEW | 235k | 19.33 | |
| Sangamo Biosciences (SGMO) | 0.4 | $4.4M | 761k | 5.81 | ||
| Iveric Bio (ISEE) | 0.4 | $4.4M | -25% | 260k | 16.83 | |
| 1life Healthcare (ONEM) | 0.4 | $4.2M | -29% | 375k | 11.08 | |
| Oak Street Health (OSH) | 0.4 | $4.0M | -31% | 150k | 26.88 | |
| Revance Therapeutics (RVNC) | 0.4 | $3.9M | NEW | 198k | 19.50 | |
| Rigel Pharmaceuticals Com New (RIGL) | 0.4 | $3.8M | -15% | 1.3M | 2.99 | |
| Intellia Therapeutics (NTLA) | 0.4 | $3.6M | NEW | 50k | 72.68 | |
| Accolade (ACCD) | 0.3 | $3.5M | -4% | 200k | 17.56 | |
| Myovant Sciences (MYOV) | 0.3 | $3.3M | 249k | 13.32 | ||
| Nektar Therapeutics (NKTR) | 0.3 | $3.3M | -35% | 614k | 5.39 | |
| Phathom Pharmaceuticals (PHAT) | 0.3 | $3.2M | +26% | 235k | 13.61 | |
| Biogen Idec (BIIB) | 0.3 | $3.2M | -86% | 15k | 210.60 | |
| Phreesia (PHR) | 0.3 | $3.1M | -5% | 117k | 26.36 | |
| Stereotaxis Com New (STXS) | 0.3 | $3.0M | 797k | 3.73 | ||
| Viewray (VRAY) | 0.3 | $2.9M | -5% | 735k | 3.92 | |
| Ionis Pharmaceuticals (IONS) | 0.3 | $2.6M | -5% | 71k | 37.04 | |
| Essa Pharma Com New (EPIX) | 0.3 | $2.5M | -2% | 411k | 6.18 | |
| Macrogenics (MGNX) | 0.2 | $2.5M | -4% | 287k | 8.81 | |
| Olink Hldg Ab Sponsored Ads (OLK) | 0.2 | $2.5M | 140k | 17.66 | ||
| G1 Therapeutics (GTHX) | 0.2 | $2.4M | -2% | 316k | 7.60 | |
| Olema Pharmaceuticals (OLMA) | 0.2 | $2.1M | 500k | 4.26 | ||
| Rapid Micro Biosystems Class A Com (RPID) | 0.2 | $2.0M | +52% | 300k | 6.79 | |
| Pieris Pharmaceuticals (PIRS) | 0.1 | $909k | 300k | 3.03 | ||
| Annexon (ANNX) | 0.1 | $683k | 250k | 2.73 | ||
Past Filings by Rhenman & Partners Asset Management AB
SEC 13F filings are viewable for Rhenman & Partners Asset Management AB going back to 2013
- Rhenman & Partners Asset Management AB 2022 Q1 filed May 13, 2022
- Rhenman & Partners Asset Management AB 2021 Q4 filed Feb. 11, 2022
- Rhenman & Partners Asset Management AB 2021 Q3 filed Nov. 12, 2021
- Rhenman & Partners Asset Management AB 2021 Q2 filed Aug. 13, 2021
- Rhenman & Partners Asset Management AB 2021 Q1 filed May 14, 2021
- Rhenman & Partners Asset Management AB 2020 Q4 filed Jan. 19, 2021
- Rhenman & Partners Asset Management AB 2020 Q3 filed Oct. 13, 2020
- Rhenman & Partners Asset Management AB 2020 Q2 filed July 16, 2020
- Rhenman & Partners Asset Management AB 2020 Q1 filed April 16, 2020
- Rhenman & Partners Asset Management AB 2019 Q4 filed Jan. 17, 2020
- Rhenman & Partners Asset Management AB 2019 Q3 filed Oct. 16, 2019
- Rhenman & Partners Asset Management AB 2019 Q2 filed July 22, 2019
- Rhenman & Partners Asset Management AB 2019 Q1 filed April 11, 2019
- Rhenman & Partners Asset Management AB 2018 Q4 filed Feb. 5, 2019
- Rhenman & Partners Asset Management AB 2018 Q3 filed Oct. 3, 2018
- Rhenman & Partners Asset Management AB 2018 Q2 filed July 20, 2018